Table 3. Severe immune-related adverse events.
Pembrolizumab, N=26 (65%) Nivolumab, N=14 (35%) | Ipilimumab, N=40 | |
---|---|---|
Grade 3/4 irAEs–no. (%) | 3 (8) | 14 (35%) |
Hypothyroidism–1 | Colitis/diarrhoea–9 | |
Panhypopituitarism–1 | Pneumonitis–3 | |
Bullous pemphigoid–1 | Hepatitis–2 | |
Encephalitis–1 |
Abbreviation: irAE=immune-related adverse event.